Deciphera Pharmaceuticals, Inc.

Equities

DCPH

US24344T1016

Biotechnology & Medical Research

Market Closed - Nasdaq 16:00:00 2024-06-10 EDT 5-day change 1st Jan Change
25.59 USD +0.08% Intraday chart for Deciphera Pharmaceuticals, Inc. -.--% +58.65%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Ono Pharmaceutical Closes Deciphera Deal for About $2.4 Billion DJ
Deciphera Pharmaceuticals, Inc. Announces Board and Committee Changes CI
Deciphera Pharmaceuticals Acquired by Ono Pharmaceutical for $2.4 Billion MT
Deciphera Pharmaceuticals, Inc.(NasdaqGS:DCPH) dropped from NASDAQ Composite Index CI
Deciphera Pharmaceuticals, Inc.(NasdaqGS:DCPH) dropped from S&P Global BMI Index CI
Deciphera Pharmaceuticals, Inc.(NasdaqGS:DCPH) dropped from S&P TMI Index CI
Deciphera Pharmaceuticals, Inc.(NasdaqGS:DCPH) dropped from S&P Biotechnology Select Industry Index CI
Deciphera Pharmaceuticals, Inc.(NasdaqGS:DCPH) dropped from NASDAQ Biotechnology Index CI
Deciphera Pharmaceuticals Announces Oral Presentation of Results from Motion Pivotal Phase 3 Study of Vimseltinib in Patients with Tenosynovial Giant Cell Tumor At the 2024 Asco Annual Meeting and Online Publication in the Lancet CI
Deciphera Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
North American Morning Briefing : Traders Wait for -2- DJ
Barclays Upgrades Deciphera Pharmaceuticals to Equalweight From Underweight, Price Target is $26 MT
Leerink Downgrades Deciphera Pharmaceuticals to Market Perform, Price Target at $25.60 MT
JMP Downgrades Deciphera Pharmaceuticals to Market Perform MT
North American Morning Briefing : More Earnings -2- DJ
Japan's Ono Pharma says $2.4 bln Deciphera purchase 'first step' for global expansion RE
US Equity Markets Close Higher Monday Ahead of Earnings, Fed Meeting This Week MT
Sector Update: Health Care Stocks Edge Higher Late Afternoon MT
Top Midday Gainers MT
Sector Update: Health Care Stocks Rise in Monday Afternoon Trading MT
Sector Update: Health Care MT
JonesTrading Downgrades Deciphera Pharmaceuticals to Hold From Buy, Adjusts Price Target to $25.60 From $16 MT
Deciphera Agrees to $2.4 Billion Buyout Offer From Japan's ONO Pharmaceutical MT
Jefferies Downgrades Deciphera Pharmaceuticals to Hold From Buy, Trims Price Target to $25.60 From $26 MT
Deciphera Shares Hit 2-Year High After $2.4 Billion Buyout Offer From ONO Pharma DJ
Chart Deciphera Pharmaceuticals, Inc.
More charts
Deciphera Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing new medicines to improve the lives of people with cancer. The Company is leveraging its switch-control kinase inhibitor platform in kinase biology to develop a portfolio of medicines. The Company's QINLOCK, is a switch-control kinase inhibitor, engineered using its drug discovery platform and developed for the treatment of fourth-line gastrointestinal stromal tumor (GIST). In addition to QINLOCK, it has developed a robust pipeline of drug candidates using its switch-control kinase inhibitor platform, including vimseltinib and DCC-3116. Vimseltinib is an investigational, orally administered, potent, and highly-selective switch-control kinase inhibitor of colony stimulating factor 1 receptor (CSF1R) kinase for the potential treatment of tenosynovial giant cell tumor (TGCT). DCC-3116 is a Phase 1/2 inhibitor of ULK kinases being developed to inhibit autophagy.
Related indices
More about the company